GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial,

April 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused … AML accounts for roughly 1.8% of cancer deaths in the United States. About …, April 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused … AML accounts for roughly 1.8% of cancer deaths in the United States. About …, Read More

Scroll to Top